A recent study by Kaplan et al indicated that ER+BRCA1-related breast cancers are indistinguishable from ER−BRCA1-related cancers in their nuclear expression of PARP-1, suggesting that ER+BRCA1-related breast cancers may respond well to drugs that exploit BRCA1 deficiency (15). This evidence concerns the gene PARP1 and breast cancer.